Notable decrease patient albuminuria;
显著减少患者蛋白尿；
To has the clinical albuminuria patient.
对有临床蛋白尿的患者。
The primary end point was a change in albuminuria.
主要终点为蛋白尿改变。
Dysfunction of this retrieval pathway leads to albuminuria.
而这种重吸收作用受损就会导致蛋白尿发生。
It enriches the thoughts for the treatment of renal albuminuria.
丰富了蛋白尿的治疗思路。
This association is largely independent of the level of albuminuria.
这种相关性很大程度上不依赖于蛋白尿的水平。
The curative effect on albuminuria was better than that on hematuria.
蛋白尿疗效优于血尿疗效。
The curative effect on syndrome, albuminuria and hematuria were observed.
观察证候疗效、蛋白尿和血尿疗效。
However, the link between early albuminuria and adiposity remains unclear.
然而，最初的蛋白尿和肥胖症之间的联系仍不清楚。
Fever, albuminuria, weight loss, and vomiting are the most common symptoms.
发烧，蛋白尿，体重减轻，及呕吐是最常见的症状。
Conclusion: Yishen Fluid is effective pharmaceutics in treating glomerulus albuminuria.
结论：益肾液是治疗肾小球蛋白尿的有效制剂。
Can treatment aimed at reducing albuminuria lead to cardiovascular risk reduction as well?
旨在降低蛋白尿的治疗是否同样可以减少心血管疾病的风险？
Albuminuria is the best available surrogate parameter in the treatment of diabetic nephropathy.
蛋白尿是糖尿病肾病治疗最好用的代表参数。
Objective: To observe the therapeutic effect on glomerulus albuminuria treated by Yishen Fluid.
目的：观察益肾液治疗肾小球性蛋白尿的疗效。
Albuminuria and DR should be considered as risk factors of renal prognosis in type 2 diabetic patients.
蛋白尿和DR应被视为2型糖尿病患者肾脏预后的危险因素。
In ACCORD Lipid, fenofibrate also reduced micro - and macro-albuminuria, markers of diabetic renal disease.
在ACCORD脂质研究基金会，非诺贝特同时降低了微观及宏观尿蛋白量，二者都是胰岛肾病的标志。
But our patients have very low albuminuria baseline and many of them will never develop diabetic nephropathy.
我们患者的基线白蛋白尿水平本来就很低，他们中的很多人根本就不会发生糖尿病肾病。
But if they have albuminuria then the risk is elevated for the cardiovascular but in particular for the kids.
但是如果出现蛋白尿，那么心血管病风险就增加了，但对儿童则不一定。
Objective: To observe the effect of Shenshu capsule match hormone in the treatment of heavy kidney albuminuria.
目的：观察肾舒胶囊配合激素等西药治疗重度肾性蛋白尿的效果。
Quota of albuminuria not only is important to diagnose the renopathy, but also its can aggravate the kidney damage.
蛋白尿的多少不但对肾脏病的诊断治疗、预后的判断有着重要意义，而且其本身又加重了肾脏的损伤。
Reductions in albuminuria, a hallmark of early diabetic kidney disease, have been reported in initial human trials.
白蛋白是糖尿病早期肾脏病变的特征，在最初的人类实验中已经报道了白蛋白尿的减少。
However, there was no significant association between albuminuria and HF in patients taking antihypertensive treatment.
然而，在接受抗高血压药物治疗的患者中，蛋白尿和HF没有显著相关性。
Based on our data we hypothesize that weight-induced changes in vascular inflammation may cause changes in albuminuria.
根据我们的资料，我们猜测体重变化引起的血管炎能引起蛋白尿的变化。
The impact of weight change on albuminuria and its possible mechanism has not been studied yet in the general population.
在一般人群中，体重变化对蛋白尿的影响及可能的作用机制尚未被研究。
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.
预测因子与2型糖尿病肾病和高血压患者心血管事件的预测因子：蛋白尿因素。
Acute Kidney Injury Predicts Major Adverse Outcomes in Diabetes: Synergic Impact With Low Glomerular Filtration Rate and Albuminuria.
急性肾损伤的预测糖尿病的主要不良后果：协同影响低肾小球滤过率和蛋白尿。
Objective To investigate the effects of the combination of low molecular weight heparin and ACEI on albuminuria in diabetic nephropathy.
目的观察低分子肝素联合血管转换酶抑制剂对糖尿病肾病显性蛋白尿的治疗效果。
If hypertension and so on, the chronic kidney fades may be accompanied by the primary disease's performance, like hematuria, albuminuria and so on.
如高血压等，慢性肾衰可伴有原发疾病的表现，如血尿、蛋白尿等。
Cuj. Cujus 13 of them were glomerular proteinuria, 9 tubuloproteinuria, 11 mixed albuminuria, 2 overflow proteinuria and 5 physiologic proteinuria.
其中肾小球性蛋白尿13例、肾小管性蛋白尿9例、混合性蛋白尿11例、溢出性蛋白尿2例、生理性蛋白尿5例。
Cuj. Cujus 13 of them were glomerular proteinuria, 9 tubuloproteinuria, 11 mixed albuminuria, 2 overflow proteinuria and 5 physiologic proteinuria.
其中肾小球性蛋白尿13例、肾小管性蛋白尿9例、混合性蛋白尿11例、溢出性蛋白尿2例、生理性蛋白尿5例。
应用推荐